Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

VolitionRx Limited (VNRX)

2.31   0.08 (3.59%) 11-25 13:00
Open: 2.25 Pre. Close: 2.23
High: 2.38 Low: 2.21
Volume: 190,976 Market Cap: 133(M)

Technical analysis

as of: 2022-11-28 8:52:26 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.77     One year: 3.24
Support: Support1: 1.91    Support2: 1.62
Resistance: Resistance1: 2.38    Resistance2: 2.77
Pivot: 1.89
Moving Average: MA(5): 2.13     MA(20): 1.9
MA(100): 1.83     MA(250): 2.37
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 94.5     %D(3): 89.7
RSI: RSI(14): 73.4
52-week: High: 3.56  Low: 1.3
Average Vol(K): 3-Month: 106 (K)  10-Days: 151 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VNRX ] has closed above the upper band by 0.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 81.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.38 - 2.39 2.39 - 2.4
Low: 2.19 - 2.2 2.2 - 2.21
Close: 2.29 - 2.31 2.31 - 2.32

Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Headline News

Tue, 15 Nov 2022
VolitionRx Limited (VNRX) Q3 2022 Earnings Call Transcript - Seeking Alpha

Mon, 14 Nov 2022
VolitionRX: Q3 Earnings Snapshot - Danbury News Times

Mon, 14 Nov 2022
Volition Announces Clinical Research Study with Oncovet - VolitionRX (AMEX:VNRX) - Benzinga

Mon, 14 Nov 2022
VolitionRX reports Q3 results (NYSE:VNRX) - Seeking Alpha

Wed, 09 Nov 2022
VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update - Valdosta Daily Times

Thu, 03 Nov 2022
VNRX: Global Supply Agreement for Nu.Q Vet Cancer Test with a market leader in pet healthcare. U.S. Clinical studies for Nu.Q NETs are planned to pave the way for FDA approval. - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 48 (M)
Shares Float 25 (M)
% Held by Insiders 44.4 (%)
% Held by Institutions 7.8 (%)
Shares Short 1,370 (K)
Shares Short P.Month 1,420 (K)

Stock Financials

EPS -0.45
EPS Est Next Qtl -0.16
EPS Est This Year -0.56
EPS Est Next Year -0.57
Book Value (p.s.) 0.4
Profit Margin (%) 0
Operating Margin (%) -83145.4
Return on Assets (ttm) -48.4
Return on Equity (ttm) -106.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.39
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio -5.17
PEG Ratio 0
Price to Book value 5.77
Price to Sales 4848.67
Price to Cash Flow -7.12

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.